In this report, we provided evidence for this hypothesis by demonstrating that GBM cells treated with a HOXA13 siRNA showed decreased expression of p-SMAD2 and p-SMAD3 in nucleus with no significant change in the total SMAD2 and SMAD3 expression levels. This evidence concerns the gene SMAD2 and glioblastoma.